<DOC>
	<DOCNO>NCT00544882</DOCNO>
	<brief_summary>This multi-center study evaluate hormone level oral contraceptive regimen DR-1021 .</brief_summary>
	<brief_title>A Study Evaluate Hormone Patterns Ovarian Follicular Activity With DR-1021</brief_title>
	<detailed_description>Female volunteer , age 18-35 year old meet Inclusion Exclusion Criteria , enrol study . All participant current user standard 21/7 oral contraceptive regimen ( 21 day combination progestin/estrogen follow 7 day placebo ) complete least one 28-day cycle prior begin Cycle 1 baseline cycle . After complete screening , enrol participant continue receive regimen 150 μg DSG /20 μg EE combination pill daily 21 day follow placebo daily 7 day Cycle 1 ( Run-In phase ) . Following completion Cycle 1 , participant randomly assign receive either DR-1021 Mircette Cycle 2 . All participant complete Cycle 2 receive Kariva Cycle 3 ; however , participant follow first 21 day 28-day regimen , consider study completers .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Oviol</mesh_term>
	<criteria>Premenopausal Weight &lt; 200 lb Currently take willing treated oral contraceptive standard 21/7 regimen one cycle prior start Study Cycle 1 Others dictate protocol Any contraindication use oral contraceptive Breast feed Smoking &gt; 10 cigarette per day Use drug require simultaneous use contraceptive ( e.g. , isotretinoin [ Accutane ] ) Others dictate protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>